Pam Taub, MD
Cardiovascular Disease · la Jolla, CANPI 1346355161
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 14.8%. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 913 payments — averaging $1325.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$179K
- Novo Nordisk AS$175K
- Novo Nordisk$134K
- Lilly USA, LLC$83K
- Medtronic$77K
- Eli Lilly$58K
- plus $505K from 41 others
Across 541 payments — averaging $3653.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$1.3M
- Novartis$405K
- Amgen$74K
- CSL Behring$50K
- Applied Therapeutics, Inc.$43K
- Novartis Pharma AG$38K
- plus $74K from 7 others
What the payments were for
- Consulting fees$585,16748%
- Speaking & faculty fees$379,31231%
- Travel & lodging$225,56719%
- Food & beverage$19,9322%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$186,191
- Saxenda$62,071
- Victoza$37,447
- LEQVIO$37,234
- Kerendia$37,169
- PRALUENT$29,607
- XARELTO$29,369
- NEXLETOL$29,115
- MULTAQ$29,080
- NEXLIZET$28,746
- SYMPLICITY G3$27,850
- XYWAV$25,418
- Repatha$24,992
- Vascepa$21,325
- Korlym$20,608
- SYNERGY ABLATION SYSTEM$15,490
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$15,112
- Ozempic$14,288
- RYBELSUS$11,745
- CoreValve Evolut$11,550
How this compares
$1,210,011 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $226,278 |
| JardianceEmpagliflozin | 115 | $139,615 |
| XareltoRivaroxaban | 59 | $90,626 |
| OzempicSemaglutide | 84 | $89,322 |
| Repatha SureclickEvolocumab | 110 | $88,213 |
| Praluent PenAlirocumab | 50 | $35,016 |
| KerendiaFinerenone | 17 | $30,245 |
| CorlanorIvabradine Hcl | 27 | $29,205 |
| NexletolBempedoic Acid | 24 | $27,608 |
| Repatha SyringeEvolocumab | 18 | $19,045 |
| EntrestoSacubitril/Valsartan | 17 | $16,499 |
| Droxidopa | 41 | $14,039 |
| MounjaroTirzepatide | 11 | $10,706 |
| VascepaIcosapent Ethyl | 15 | $7,041 |
| Ivabradine Hcl | 15 | $6,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $4,168 | $226,278202 claims |
| Boehringer IngelheimJardiance | $179,315 | $139,615115 claims |
| Johnson & JohnsonXarelto | $25,494 | $90,62659 claims |
| Novo NordiskOzempic | $133,910 | $89,32284 claims |
| BayerKerendia | $44,680 | $30,24517 claims |
| AmgenCorlanor | $54,978 | $29,20527 claims |
| Esperion Therapeutics, Inc.Nexletol | $29,695 | $27,60824 claims |
| NovartisEntresto | $38,927 | $16,49917 claims |
| Lilly USA, LLCMounjaro | $82,544 | $10,70611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in la Jolla
- Eric Topolla Jolla$2.2M
- Douglas Gibsonla Jolla$727K
- Douglas Triffonla Jolla$176K
- Judith Swainla Jolla$151K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.